Annovis Bio (NYSE: ANVS), a leader in developing treatments for neurodegenerative diseases, was recently featured on Today’s Marketplace in an exclusive interview with Dr. Maria Maccecchini, Founder, President, and CEO. Dr. Maccecchini detailed Annovis Bio’s groundbreaking drug development targeting toxic … Continue reading →

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), will hold a live investor webcast on Dec. 11, 2024, at 4:30 p.m. EST, to … Continue reading →

Annovis Bio (NYSE: ANVS), a clinical-stage company developing therapies for neurodegenerative diseases, will host a live investor webcast on Dec. 11, 2024, at 4:30 PM EST. Led by Founder and CEO Dr. Maria Maccecchini, the event will highlight updates on … Continue reading →

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently achieved a significant milestone in its drug development process. In early October, the … Continue reading →

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), concluded the third quarter with significant milestones achieved and a clear path forward for its … Continue reading →

Annovis Bio (NYSE: ANVS) announced that its President and CEO, Dr. Maria Maccecchini, will speak at the National Institute on Aging’s (NIA) workshop, “Dementia with Lewy Bodies: Filling the Gaps in Translational and Clinical Research.” Scheduled for Nov. 13, 2024, Dr. … Continue reading →

Annovis (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), presented two scientific posters at the 17th Clinical Trials on Alzheimer’s Disease (“CTAD”) conference (https://ibn.fm/ysPFn), held … Continue reading →

Annovis Bio (NYSE: ANVS) led by Founder, President and CEO Dr. Maria Maccecchini, shares exciting developments regarding its pioneering Alzheimer’s and Parkinson’s drug candidate, buntanetap. In her interview on IBN’s BioMedWire Podcast, Dr. Maccecchini discusses Annovis Bio’s recent FDA clearance … Continue reading →

Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering novel therapies for neurodegenerative diseases. Recent clinical trials of the company’s lead compound yielded encouraging results, with buntanetap shown to improve cognition in both Alzheimer’s and Parkinson’s patients. … Continue reading →

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently secured the approval of the U.S. Food and Drug Administration (“FDA”) to pursue Phase … Continue reading →